Market Intelligence, Hippo Pathway Biology, and High-Purity Reagents for SAV1/TEAD-axis Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SAV1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SAV1 Full-Length & SARAH-Domain Recombinant Protein (WT + Cancer Mutants) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Also available: SARAH domain deletion mutant (Δ401-522) and phosphorylation-deficient controls (S275A, T277A). |
View SAV1 Products |
| Gene Delivery | SAV1 Promise-ORF / Lentivirus Full-length ORF for stable rescue in SAV1-deficient cell lines. CMV promoter, Puromycin selection. High titer (10^8 TU/mL). |
View SAV1 Products |
| Benchmark Ab | Anti-SAV1 Recombinant Rabbit mAb Sequence-defined positive control for Western blot, IHC, and Co-IP. Epitope mapped outside conserved SARAH motif. |
View SAV1 Products |
| Validator | SAV1 siRNA Set For knockdown verification and YAP/TAZ pathway specificity control. Three-target pool plus negative control. |
View SAV1 Products |
| Related Target A | YAP1 Downstream transcriptional co-activator; essential Hippo pathway readout. |
View YAP1 Products |
| Related Target B | STK3 (MST2) Direct SARAH-domain kinase partner; core Hippo cassette component. |
View STK3 Products |
| Related Target C | TEAD1 Terminal transcription factor; synthetic lethal dependency with SAV1 loss. |
View TEAD1 Products |
| Related Target D | MST1 (STK4) Parallel upstream kinase for SARAH dimerization assays. |
View MST1 Products |
| Related Target E | LATS1 WW domain binding partner; downstream effector for scaffold validation. |
View LATS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SARAH-domain PPI disruption (SAV1-MST1/2) | Purified WT & truncation mutant proteins with verified SARAH-domain sequence >95% purity by SDS-PAGE Recombinant SARAH domain fragments (aa 401-522) available |
| WW Domain Specificity (PPxY motif binding) | Full-length SAV1 with intact dual WW domains (aa 354-414) Endotoxin controlled for sensitive cell-based assays |
| Phosphorylation Site Mapping | Mutant SAV1 (S275A, T277A) phosphorylation-deficient controls Sequence-verified alanine substitutions |
| Loss-of-function pathway reconstruction | High-titer SAV1 lentivirus particles (10^8 TU/mL) for stable rescue in SAV1-null HCC/CRC backgrounds HEK293T packaging ensuring native folding |
| Off-target within Hippo family (SARAH homology) | Anti-SAV1 mAb with mapped epitope outside the conserved SARAH motif Ortholog panels verified by mass spectrometry |
| False positives in genetic rescue | Validated SAV1 siRNA set included for knockdown specificity checks SARAH domain deletion mutant as negative binding control |
Live SAV1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Hippo pathway therapeutics is intensifying, with major players shifting focus from direct kinase inhibition to downstream TEAD and YAP/TAZ modulation. While SAV1 itself is a tumor-suppressive scaffold with limited direct clinical targeting to date, its loss-of-function mutations are emerging as critical biomarkers for patient stratification. SAV1 loss is widely implicated in solid tumors including colorectal cancer (CRC), hepatocellular carcinoma (HCC), clear cell renal cell carcinoma (ccRCC), and mesothelioma. Because restoring a tumor suppressor directly via small molecules is inherently difficult, the market is aggressively pivoting toward synthetic lethality—targeting downstream effectors like TEAD1/2/3/4 or YAP/TAZ complexes in SAV1-deficient environments. As first-generation TEAD inhibitors (e.g., VT3989, IK-930) advance through Phase 1/2 trials, the next wave of R&D is focusing on molecular glues to stabilize mutant SAV1-MST complexes, mRNA-based gene therapies for functional restoration, and PROTAC degraders of YAP/TAZ. Future outlook predicts that companion diagnostics integrating SAV1 mutation status will become standard by 2028, and the market for SAV1-directed therapies (including combination regimens) could reach $15-20 billion by 2028.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (TEAD/YAP axis) | Vivace Therapeutics, Eli Lilly, Ikena Oncology | NF2-deficient tumors, HCC, NSCLC, ccRCC, Mesothelioma | Synthetic lethality screening in SAV1-null models (Need SAV1 siRNA and lentivirus rescue) |
| Molecular Glue / PPI Stabilizer | Nurix, Arvinas, Kymera, emerging biotech | SAV1-mutant CRC, HCC, liver cancer | PPI stabilization assays (Need high-purity SAV1/MST1/2 mutant proteins and SARAH domain panel) |
| Gene Therapy / mRNA | Novartis, Roche, academic consortia | SAV1-null solid tumors | Functional restoration (Need full-length ORF lentivirus and strictly characterized anti-SAV1 antibodies) |
| PROTAC (YAP/TAZ Degraders) | Arvinas, Kymera Therapeutics | Refractory cancers with Hippo inactivation | Pathway reconstitution (Need stable cell lines expressing SAV1 WT/mutant) |
| Synthetic Lethality (non-TEAD) | Recursion, insitro | Colorectal cancer | Pathway node validation (Need complete Hippo protein panel: MST1/2, LATS1/2, YAP) |
| Biomarker / Companion Diagnostic | Diagnostic developers | Solid tumors with Hippo inactivation | Isoform-specific antibodies, siRNA controls, and mutation-specific recombinant proteins |